Microcap Ledger Quantum Cyber N.V. $QUCY
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Mainz
- Fiscal year end
- December 31
- Shares outstanding
- 84,068,192 [10-Q 2026-08-14]
What the company doesAI summary of filing
Quantum Cyber N.V. (formerly Mainz Biomed N.V.) historically developed and sold in-vitro diagnostic tests for early cancer detection. In March 2025, the company acquired an exclusive license to mRNA biomarkers and an AI algorithm for non-invasive blood-based pancreatic cancer detection, and is developing PancAlert, a stool-based pancreatic cancer screening test. The company sold its ColoAlert colorectal cancer screening product intellectual property in March 2026 and is seeking to sell intellectual property for a next-generation colorectal cancer screening product. As of March 30, 2026, the company is headquartered in Germany with approximately 13 employees and is currently refocusing its business strategy toward post-quantum cybersecurity while continuing pancreatic cancer product commercialization efforts. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$16.10M | −$9.90M | $13.40M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $537.1K | −$16.21M | −$10.98M | $889.1K | [10-K 2026-03-31] |
| FY ended Dec 2024 | $894.0K | −$21.60M | −$17.33M | $6.24M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$4.95M
- Cash runway Estimate
- ~8.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2023-12-31 | 21,165,482 | [20-F 2024-04-09] |
| 2024-12-31 | 2,319,353 | [20-F 2025-03-31] |
| 2026-03-30 | 12,515,336 | [10-K 2026-03-31] |
| 2026-05-14 | 14,661,169 | [10-Q 2026-05-15] |
| 2026-08-13 | 84,068,192 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-06-04; declared effective 2026-06-15 [S-3 2026-06-04]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-05 | Lazar David E. | other | 9,000,000 | $9.00 | [4 2026-08-07] |
| 2026-08-05 | Lazar David E. | other | 9,000,000 | $9.00 | [4 2026-08-07] |
| 2026-08-05 | Lazar David E. | other | 9,000,000 | $9.00 | [4 2026-08-07] |
| 2026-08-05 | Lazar David E. | other | 28,057,500 | $225.00 | [4 2026-08-07] |
| 2026-07-31 | Ben-Tzvi Avraham | grant | 112,259 | — | [4 2026-08-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Material agreement entered |
| 2026-10-09 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-25 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-10 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-24 | 8-K | Regulation FD disclosure |
| 2026-07-16 | 8-K | Acquisition or disposition completed; Regulation FD disclosure; Other events |
| 2026-07-07 | 8-K | Director or officer change |
| 2026-07-01 | 8-K | Material agreement entered; Other events |
| 2026-06-26 | 8-K | Auditor change |
| 2026-06-15 | 8-K | Material agreement entered; Regulation FD disclosure |
Alerts for $QUCY
Email me when Quantum Cyber N.V. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.